Mitigation strategies to safely conduct HIV treatment research in the context of COVID‐19

The International AIDS Society convened a multidisciplinary committee of experts in December 2020 to provide guidance and key considerations for the safe and ethical management of clinical trials involving people living with HIV (PLWH) during the SARS‐CoV‐2 pandemic. This consultation did not discuss guidance for the design of prevention studies for people at risk of HIV acquisition, nor for the programmatic delivery of antiretroviral therapy (ART).

[1]  Richard D Moore,et al.  Factors Associated With Severity of COVID-19 Disease in a Multicenter Cohort of People With HIV in the United States, March–December 2020 , 2022, Journal of acquired immune deficiency syndromes.

[2]  T. Peto,et al.  Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants , 2022, The New England journal of medicine.

[3]  S. Karim,et al.  Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic , 2021, The Lancet.

[4]  I. Torjesen.  Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear , 2021, BMJ.

[5]  Richard D Moore,et al.  Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020 , 2021, medRxiv : the preprint server for health sciences.

[6]  I. Diamond,et al.  Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK , 2021, Nature Medicine.

[7]  D. Fisman,et al.  Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada , 2021, Canadian Medical Association Journal.

[8]  O. A. Ogun,et al.  Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study , 2021, The Lancet.

[9]  J. Wise.  Vaccinating against covid and flu at same time is safe, study shows , 2021, BMJ.

[10]  A. Ryo,et al.  Neutralizing efficacy of vaccines against the SARS-CoV-2 Mu variant , 2021, medRxiv.

[11]  Michael I. Mandel,et al.  Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel , 2021, The New England journal of medicine.

[12]  W. Steward,et al.  COVID-19 Vaccine Hesitancy Among PLWH in South India: Implications for Vaccination Campaigns , 2021, Journal of acquired immune deficiency syndromes.

[13]  A. Iwasaki,et al.  COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants , 2021, Cell.

[14]  L. Galea,et al.  Intention to Receive a COVID-19 Vaccine by HIV Status Among a Population-Based Sample of Women and Gender Diverse Individuals in British Columbia, Canada , 2021, AIDS and Behavior.

[15]  G. Tomlinson,et al.  Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients , 2021, The New England journal of medicine.

[16]  O. Laeyendecker,et al.  The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV) , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  R. Myers,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.

[18]  D. Segev,et al.  Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. , 2021, AIDS.

[19]  T. Padma.  COVID vaccines to reach poorest countries in 2023 — despite recent pledges , 2021, Nature.

[20]  J. Izopet,et al.  Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients , 2021, The New England journal of medicine.

[21]  P. Klenerman,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial , 2021, The Lancet HIV.

[22]  S. Maurer-Stroh,et al.  Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta) , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Dagpunar.  Interim estimates of increased transmissibility, growth rate, and reproduction number of the Covid-19 B.1.617.2 variant of concern in the United Kingdom , 2021, medRxiv.

[24]  P. Maes,et al.  Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters , 2021, EBioMedicine.

[25]  D. Moodley,et al.  Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant , 2021, The New England journal of medicine.

[26]  V. Chinchilli,et al.  Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis , 2021, Scientific Reports.

[27]  L. Danon,et al.  Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study , 2021, BMJ.

[28]  C. Denkinger,et al.  Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis , 2021, medRxiv.

[29]  R. Soto-Rifo,et al.  Performance of SARS-CoV-2 rapid antigen test compared with real-time RT-PCR in asymptomatic individuals , 2021, International Journal of Infectious Diseases.

[30]  David R. Holtgrave,et al.  COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State , 2021, JAMA network open.

[31]  K. Bhaskaran,et al.  HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform , 2020, The Lancet HIV.

[32]  L. Waters,et al.  COVID-19 death in people with HIV: interpret cautiously , 2020, The Lancet HIV.

[33]  S. Lewin,et al.  HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper , 2020, Journal of Virus Eradication.

[34]  M. Esposito,et al.  SARS-CoV-2 Infections and COVID-19 Fatality: Estimation of Infection Fatality Ratio and Current Prevalence , 2020, International journal of environmental research and public health.

[35]  M. Gandhi,et al.  The interplay between HIV and COVID-19: summary of the data and responses to date , 2020, Current opinion in HIV and AIDS.

[36]  Samir Bhatt,et al.  Report 34: COVID-19 infection fatality ratio: estimates from seroprevalence , 2020 .

[37]  C. Sabin,et al.  Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  P. Sax,et al.  Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients with HIV and Coronavirus Disease-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  C. Giaquinto,et al.  SARS‐CoV‐2 infection in people living with HIV: a systematic review , 2020, Reviews in medical virology.

[40]  L. Morris,et al.  Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  M. Peluso,et al.  Operationalizing Human Immunodeficiency Virus Cure-related Trials with Analytic Treatment Interruptions During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: A Collaborative Approach , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[42]  L. Calza,et al.  Factors associated with hospital admission for COVID-19 in HIV patients. , 2020, AIDS.

[43]  B. Woodward,et al.  Coronavirus disease 2019 (COVID‐19) outcomes in HIV/AIDS patients: a systematic review , 2020, HIV medicine.

[44]  Kemesha S Gabbidon,et al.  The Impact of COVID-19 on HIV Treatment and Research: A Call to Action , 2020, International journal of environmental research and public health.

[45]  P. Horby,et al.  Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.

[46]  Joe Hasell,et al.  Coronavirus disease (COVID-19) , 2020, Arab Society: A Compendium of Social Statistics.

[47]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[48]  E. Bass,et al.  P15-21. Investigating the utility and relevance of the good participatory practice guidelines for biomedical HIV prevention trials , 2009, Retrovirology.

[49]  P. Horby,et al.  Edinburgh Research Explorer Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020 .